SeamlessBio · Cell4Pharma · FDA 2020 · EMA 2012 · ICH M12 · DACH Exclusive
DMPK & ABC Transporter Assays — Vesicle Kits for FDA/EMA DDI Studies
Drug metabolism and pharmacokinetics (DMPK) studies are mandatory for all new molecular entities (NMEs) before IND submission to the FDA or CTA submission to the EMA. SeamlessBio supplies the Cell4Pharma range of ABC transporter membrane vesicle kits — HEK293-derived inside-out vesicles, 100 reactions per kit, full activity validation per lot, FDA/EMA DDI Guidance-compliant documentation.
Regulatory requirement — FDA 2020 & EMA 2012 DDI Guidance:
The FDA 2020 Drug Interaction Guidance and EMA 2012 DDI Guideline require evaluation of P-gp (ABCB1), BCRP (ABCG2), OATP1B1/1B3, OCT1/2, OAT1/3, MATE1/2K for all NMEs, and BSEP (ABCB11) for hepatotoxicity risk assessment. The membrane vesicle assay is the accepted in vitro method for BSEP, BCRP, P-gp, and MRP family transporters. ICH M12 (2023) harmonises FDA and EMA requirements.
Recommended DDI Testing Panels
IND-Enabling
Minimal FDA DDI Panel
Covers FDA mandatory transporters for BSEP (DILI), BCRP and P-gp (DDI). Minimum package for IND transporter section.
BSEP + BCRP + P-gp + Control Vesicles
DILI Risk Assessment
DILI Risk Panel
Complete hepatic transporter panel — dual/triple liability assessment. Identifies DILI risk from compensatory pathway inhibition beyond BSEP alone.
BSEP + MRP2 + MRP3 + MRP4 + Control
Full Coverage
Full DDI Panel
Comprehensive transporter inhibition profile for NMEs with complex ADME or known hepatic/renal metabolism. Supports complete IND DDI section.
All 11 kits — complete transporter portfolio
Complete Cell4Pharma Vesicle Kit Portfolio
| Transporter | Gene | Location | Clinical Relevance | Kit |
|---|---|---|---|---|
| BSEP | ABCB11 | Hepatocyte canalicular membrane | Drug-induced liver injury (DILI) — BSEP inhibition causes cholestatic hepatotoxicity. FDA mandatory for all NMEs. | BSEP Kit → |
| BCRP | ABCG2 | Intestine, liver, BBB, placenta | Oral bioavailability, CNS penetration, DDI with rosuvastatin, methotrexate, imatinib. FDA mandatory. | BCRP Kit → |
| P-gp (MDR1) | ABCB1 | Intestine, liver, BBB, kidney, placenta | Most clinically significant efflux transporter — oral bioavailability, CNS exclusion, multi-drug resistance. FDA mandatory. | P-gp Kit → |
| P-gp / FluoPgp | ABCB1 | As P-gp above | Fluorescent substrate-based P-gp assay — higher throughput, no radiolabel required. Compatible with standard plate reader detection. | FluoPgp Kit → |
| MRP1 | ABCC1 | Ubiquitous — basolateral liver, lung, kidney | GSH-conjugate and glucuronide efflux. Multidrug resistance in cancer. Basolateral hepatic efflux in DILI risk panel. | MRP1 Kit → |
| MRP2 | ABCC2 | Hepatocyte canalicular, intestine, kidney | Canalicular bile acid efflux — compensatory pathway when BSEP is inhibited. Dual BSEP/MRP2 inhibition = higher DILI risk. | MRP2 Kit → |
| MRP3 | ABCC3 | Basolateral hepatocyte, intestine | Basolateral bile acid safety valve — upregulated when canalicular efflux is impaired. Key element of DILI dual liability panel. | MRP3 Kit → |
| MRP4 | ABCC4 | Hepatocyte, kidney, platelet | Bile acid renal compensation pathway. Alternative efflux when hepatic routes impaired. Platelet drug transport. | MRP4 Kit → |
| MRP5 | ABCC5 | Ubiquitous — brain, heart | Nucleotide and cyclic nucleotide efflux. CNS drug resistance. Cardiac drug accumulation risk. | MRP5 Kit → |
| MRP8 | ABCC11 | Liver, brain, breast tissue | Steroid and bile acid conjugate transport. Emerging role in oncology drug resistance. | MRP8 Kit → |
| Control Vesicles | Non-transfected HEK293 | — | Required for all vesicle assays — background correction for non-specific ATP-dependent uptake. Without this, IC₅₀ values are unreliable. | Control Kit → |
Kit Specifications
| Parameter | Specification |
|---|---|
| Expression system | HEK293 — inside-out membrane vesicles overexpressing human ABC transporter |
| Reactions per kit | 100 reactions |
| Vesicle orientation | Inside-out — ATP-dependent transport into vesicle lumen (correct orientation for transport assay) |
| Substrates | Radiolabelled or MS-detectable — taurocholic acid (BSEP), estradiol glucuronide (MRP2), methotrexate (MRP), vinblastine (P-gp) |
| Lot validation | IC₅₀ with reference inhibitor per lot — cyclosporin A (BSEP/P-gp), Ko143 (BCRP), MK-571 (MRP) |
| Documentation | CoA with activity data, cell line documentation, lot-specific quality data. Available in German for EMA submissions. |
| Regulatory compliance | FDA 2020 DDI Guidance, EMA 2012 DDI Guideline, ICH M12 (2023) |
| Storage | −80°C | Avoid freeze-thaw cycles |
| Delivery DACH | 2–5 business days — EU stock in Passau. No US import delays. |
Frequently Asked Questions
Which transporters are mandatory for FDA IND submission?
The FDA 2020 Drug Interaction Guidance requires evaluation of P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, and MATE2K for all NMEs. BSEP evaluation is recommended for all NMEs as part of hepatotoxicity risk assessment. The membrane vesicle assay is the accepted method for P-gp, BCRP, BSEP, and MRP family transporters. EMA 2012 DDI Guideline requirements are broadly harmonised with the FDA list via ICH M12 (2023).
Why is the Control Vesicle Kit required for every assay?
Control vesicles from non-transfected HEK293 cells are essential for background correction in all vesicle assays. They measure non-specific ATP-dependent uptake and passive substrate accumulation without the transporter of interest. ATP-dependent transport = (signal in transporter vesicles) − (signal in control vesicles). Without this subtraction, IC₅₀ values are unreliable and non-compliant with FDA/EMA guidance. Each Cell4Pharma vesicle kit assay protocol specifies control vesicle use.
What is the dual liability concept for DILI risk assessment?
BSEP inhibition alone is necessary but not always sufficient to predict clinical DILI. Simultaneous inhibition of BSEP and MRP2 or MRP3 impairs both the primary canalicular bile acid efflux pathway and the compensatory basolateral safety valve — dramatically increasing intracellular bile acid accumulation and hepatotoxicity risk. Testing the complete BSEP/MRP2/MRP3/MRP4 panel provides a more accurate DILI risk profile than BSEP alone, and is increasingly expected by FDA reviewers during IND review.
What is the difference between the P-gp and P-gp FluoPgp kit?
The standard P-gp Vesicle Kit uses radiolabelled substrate (vinblastine) — accepted as the gold-standard method in regulatory submissions. The FluoPgp kit uses a fluorescent substrate that is compatible with standard plate reader detection without requiring radiochemistry infrastructure. Both kits give equivalent IC₅₀ values for reference inhibitors. For regulatory IND packages, either format is accepted by FDA and EMA when accompanied by the required QC data and reference inhibitor validation.
Why source Cell4Pharma kits from SeamlessBio DACH rather than US suppliers?
Most vesicle kit suppliers are US-based — leading to 7–14 day transatlantic shipping, cold-chain risk, customs delays, and time-zone support gaps. Cell4Pharma kits via SeamlessBio ship from EU stock in Passau: 2–5 business days DACH, 3–7 days wider EU, same cold chain, no import documentation. For CRO and pharma teams working to IND timelines, this supply reliability difference is significant. German-language documentation available for EMA submissions.
Request Cell4Pharma Vesicle Kits & DDI Study Design Support
ABC transporter vesicle kits from EU stock — 2–5 day DACH delivery. FDA 2020 / EMA 2012 / ICH M12 aligned documentation. Free consultation on which panel fits your IND programme.
Email: info@seamlessbio.de | +49 851 37932226
English 
Deutsch